Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ERAS NASDAQ:ETON NASDAQ:SAVA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeERASErasca$2.43-2.0%$1.69$1.01▼$3.31$689.32M1.181.46 million shs4.90 million shsETONEton Pharmaceuticals$20.93-1.0%$17.72$7.25▼$23.00$561.34M1.16357,088 shs351,351 shsSAVACassava Sciences$3.98+16.4%$2.45$1.15▼$33.98$192.27M-0.981.76 million shs4.51 million shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceERASErasca+6.44%+13.76%+54.04%+61.04%+1.64%ETONEton Pharmaceuticals+2.03%-2.67%+19.69%+34.12%+189.73%SAVACassava Sciences-4.20%+17.53%+58.33%+56.16%-86.54%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeERASErasca$2.43-2.0%$1.69$1.01▼$3.31$689.32M1.181.46 million shs4.90 million shsETONEton Pharmaceuticals$20.93-1.0%$17.72$7.25▼$23.00$561.34M1.16357,088 shs351,351 shsSAVACassava Sciences$3.98+16.4%$2.45$1.15▼$33.98$192.27M-0.981.76 million shs4.51 million shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceERASErasca+6.44%+13.76%+54.04%+61.04%+1.64%ETONEton Pharmaceuticals+2.03%-2.67%+19.69%+34.12%+189.73%SAVACassava Sciences-4.20%+17.53%+58.33%+56.16%-86.54%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceERASErasca 2.38Hold$3.7152.85% UpsideETONEton Pharmaceuticals 2.50Moderate Buy$29.6741.74% UpsideSAVACassava Sciences 1.50Reduce$2.00-49.75% DownsideCurrent Analyst Ratings BreakdownLatest SAVA, ETON, and ERAS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025ERASErascaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025ETONEton PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025SAVACassava SciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025ERASErascaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025ETONEton PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025SAVACassava SciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/3/2025ERASErascaBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Underperform$4.00 ➝ $1.008/18/2025ERASErascaMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$4.00 ➝ $2.00(Data available from 10/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookERASErascaN/AN/AN/AN/A$1.50 per shareN/AETONEton Pharmaceuticals$39.01M14.39N/AN/A$0.94 per share22.27SAVACassava SciencesN/AN/AN/AN/A$3.03 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateERASErasca-$161.65M-$0.45N/AN/AN/AN/A-31.19%-26.34%11/11/2025 (Estimated)ETONEton Pharmaceuticals-$3.82M-$0.16N/A41.86N/A-7.10%-0.73%-0.22%11/11/2025 (Estimated)SAVACassava Sciences-$24.34M-$2.55N/AN/AN/AN/A-66.16%-53.11%11/6/2025 (Estimated)Latest SAVA, ETON, and ERAS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025SAVACassava SciencesN/A-$0.18N/A-$0.92N/AN/A8/12/2025Q2 2025ERASErasca-$0.12-$0.12N/A-$0.12N/AN/A8/7/2025Q2 2025ETONEton Pharmaceuticals-$0.01-$0.10-$0.09-$0.10$16.71 million$18.93 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthERASErascaN/AN/AN/AN/AN/AETONEton PharmaceuticalsN/AN/AN/AN/AN/ASAVACassava SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioERASErascaN/A11.0311.04ETONEton Pharmaceuticals1.141.771.16SAVACassava SciencesN/A2.432.43Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipERASErasca67.78%ETONEton Pharmaceuticals27.86%SAVACassava Sciences38.05%Insider OwnershipCompanyInsider OwnershipERASErasca14.40%ETONEton Pharmaceuticals14.89%SAVACassava Sciences12.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableERASErasca120283.67 million242.82 millionOptionableETONEton Pharmaceuticals2026.82 million22.83 millionOptionableSAVACassava Sciences3048.31 million42.41 millionOptionableSAVA, ETON, and ERAS HeadlinesRecent News About These CompaniesLUCID CAPITAL MARKETS Initiates Coverage of Cassava Sciences (SAVA) with Buy RecommendationOctober 7 at 11:56 AM | msn.comCassava Sciences initiated with a Buy at Lucid CapitalOctober 6 at 1:17 PM | msn.comCassava Sciences (NASDAQ:SAVA) Insider Robert Christopher Cook Purchases 13,725 SharesOctober 3, 2025 | insidertrades.comCassava Sciences (NASDAQ:SAVA) Insider Buys $39,939.75 in StockOctober 2, 2025 | marketbeat.comCassava Sciences (SAVA): Evaluating Valuation After CEO’s Major Share Purchase and Alzheimer’s Program WithdrawalSeptember 27, 2025 | finance.yahoo.comCassava Sciences Target of Unusually High Options Trading (NASDAQ:SAVA)September 24, 2025 | marketbeat.comRichard Barry Buys 7,172 Shares of Cassava Sciences (NASDAQ:SAVA) StockSeptember 24, 2025 | insidertrades.comGoldman Sachs Group Inc. Boosts Stake in Cassava Sciences, Inc. $SAVASeptember 24, 2025 | marketbeat.comCassava Boss Buys Big As Stock CollapsesSeptember 23, 2025 | finance.yahoo.comRichard Barry Acquires 7,172 Shares of Cassava Sciences (NASDAQ:SAVA) StockSeptember 23, 2025 | marketbeat.comInsider Buying: Cassava Sciences (NASDAQ:SAVA) CEO Acquires 47,308 Shares of StockSeptember 23, 2025 | insidertrades.comRichard Barry Buys 47,308 Shares of Cassava Sciences (NASDAQ:SAVA) StockSeptember 22, 2025 | marketbeat.comCassava Sciences (NASDAQ:SAVA) CEO Richard Barry Acquires 190,633 SharesSeptember 22, 2025 | marketbeat.comCassava Sciences Releases New Corporate PresentationSeptember 8, 2025 | tipranks.comCassava Technologies Unveils AI Factory for Africa, Powered by NVIDIA SupercomputersAugust 25, 2025 | thezimbabwemail.comTCassava Sciences, Inc.: Cassava Reports Q2 2025 Financials Results and Provides Business UpdateAugust 14, 2025 | finanznachrichten.deCassava Sciences reports Q2 EPS (92c) vs 13c last yearAugust 14, 2025 | msn.comCassava Reports Q2 2025 Financials Results and Provides Business UpdateAugust 14, 2025 | globenewswire.comCassava Sciences Appoints Dr. Joseph Hulihan as Chief Medical OfficerAugust 7, 2025 | globenewswire.comGinkgo Bioworks Holdings Q2 Earnings PreviewAugust 6, 2025 | msn.comCassava Sciences Announces Positive Preclinical ResultsAugust 6, 2025 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSAVA, ETON, and ERAS Company DescriptionsErasca NASDAQ:ERAS$2.43 -0.05 (-2.02%) Closing price 04:00 PM EasternExtended Trading$2.44 +0.01 (+0.41%) As of 06:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.Eton Pharmaceuticals NASDAQ:ETON$20.93 -0.22 (-1.04%) Closing price 04:00 PM EasternExtended Trading$21.16 +0.23 (+1.12%) As of 06:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.Cassava Sciences NASDAQ:SAVA$3.98 +0.56 (+16.37%) Closing price 04:00 PM EasternExtended Trading$3.94 -0.04 (-0.98%) As of 06:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Archer Aviation Stock Is Soaring—And What Comes Next Lithium Americas: Why This 31% Rally Is More Than Just a Headline Energy Transfer's New Growth Engine Ignites Investor Interest AMD Could Double From Here—Thanks to Its Blockbuster OpenAI Deal AMD and OpenAI: A Partnership That Just Redrew the AI Map EA’s $55 Billion Deal Spurs a Shake-Up in the Gaming Sector 3 Dividend Aristocrats to Buy Before Year’s End Will Firefly’s $855M SciTec Acquisition Ignite a Stock Re-Rating? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
